DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 555-562

  López Rodríguez, Rosario ^a,b,c   Román, Manuel ^a,b   Novalbos, Jesús ^a,b   Pelegrina, Maria Laura ^a,b   Ochoa, Dolores ^a,b   Abad Santos, Francisco ^a,b,c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

antipsychotics; DRD2 Taq1A polymorphism; DRD3 Ser9Gly polymorphism; healthy volunteers; Prolactin

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; FEMALE; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEX RATIO; SINGLE DRUG DOSE;

ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROLACTIN; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REGRESSION ANALYSIS; RISPERIDONE; SEX FACTORS;

EID: 80052429423     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822cfff2     Document Type: Article

References (39)

1. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29:64-73.
2. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12:707-747. (Pubitemid 47172693)
3. Troost PW, Lahuis, BE, Hermans, MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol. 2007;27:52-57. (Pubitemid 46105764)
4. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997;7:479-484. (Pubitemid 27517576)
5. Noble EP, Blum K, Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry. 1991;48:648-654.
6. Chen CH, Wei FC, Koong FJ, et al. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry. 1997;41:827-829.
7. Guzey C, Scordo MG, Spina E, et al. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol. 2007;63:233-241. (Pubitemid 46233150)
8. Yasui-Furukori N, Saito M, Tsuchimine S, et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1491-1495.
9. Anderson GM, Scahill L, McCracken JT, et al. Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545-550. (Pubitemid 46185331)
10. Young RM, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry. 2004;185:147-151. (Pubitemid 39061458)
11. Calarge CA, Ellingrod VL, Acion L, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009;19:373-382.
12. Aklillu E, Kalow W, Endrenyi L, et al. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007;17:989-993. (Pubitemid 350293798)
13. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001;52:503-517. (Pubitemid 32195338)
14. Holmes A, Lachowicz JE, Sibley DR. Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology. 2004;47:1117-1134. (Pubitemid 39572704)
15. Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophreniaVan update. Pharmacogenomics. 2004;5:691-698. (Pubitemid 39236582)
16. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun. 1996;225:1068-1072. (Pubitemid 26319228)
17. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 1997;2:139-145. (Pubitemid 27166033)
18. Eichhammer P, Albus M, Borrmann-Hassenbach M, et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet. 2000;96:187-191. (Pubitemid 30180861)
19. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology. 2002;27:105-119. (Pubitemid 34626747)
20. Lane HY, Hsu SK, Liu YC, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol. 2005;25:6-11.
21. Novalbos J, López-Rodríguez, R, Román, M, et al. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics and safety of risperidone in healthy volunteers. J Clin Psychopharmacol. 2010;30:504-511.
22. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314. (Pubitemid 39388605)
23. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21:768-773. (Pubitemid 47437921)
24. Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol. 2006;16:317-326. (Pubitemid 43902428)
25. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14:163-173. (Pubitemid 36172565)
26. Melmed S, Kleinberg, D. Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, et al, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; 2008.
27. Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol. 1992;19:603-606.
28. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28(suppl 2):69-82. (Pubitemid 36332230)
29. de Leon J, Diaz FJ, Josiassen RC, et al. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Eur Arch Psychiatry Clin Neurosci. 2004;254:318-325. (Pubitemid 39312826)
30. Eberhard J, Lindstrom E, Holstad M, et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115:268-276. (Pubitemid 46425745)
31. Suzuki A, Kondo T, Mihara K, et al. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur Arch Psychiatry Clin Neurosci. 2001;251:57-59. (Pubitemid 32488032)
32. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23:540-545. (Pubitemid 38720604)
33. Garrido E, Palomo T, Ponce G, et al. The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine. Neurotox Res. 2011;20:32-39.
34. Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology. 1999;21:17-27. (Pubitemid 29253832)
35. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol. 1996;16:158-169. (Pubitemid 26141753)
36. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol. 2006;21:529-532. (Pubitemid 46062141)
37. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162:1010-1012. (Pubitemid 40676220)
38. Wang L, Yu L, Zhang AP, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol. 2007;21:837-842. (Pubitemid 350029187)
39. Yasui-Furukori N, Tsuchimine S, Saito M, et al. Association between major multidrug resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1230-1234. (Pubitemid 47081309)